Tag: ALTA1L

Gastroenterology

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Newsemia
Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line)...
Latest News

Takeda presenta los resultados del ensayo de fase 3 ALTA-1L que destaca la eficacia intracraneal de ALUNBRIG® (brigatinib) en comparación con crizotinib en el cáncer de pulmón amicrocítico ALK+ avanzado de primera línea

Newsemia
CAMBRIDGE, Massachusetts y OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) ha anunciado hoy que los datos de eficacia intracraneal del ensayo de fase 3...
Latest News

Takeda präsentiert Ergebnisse aus der Phase-3-Studie ALTA-1L, die die intrakranielle Wirksamkeit von ALUNBRIG® (Brigatinib) gegenüber Crizotinib in der Erstlinientherapie beim ALK-positiven…

Newsemia
CAMBRIDGE, Massachusetts (USA) und OSAKA (Japan)–(BUSINESS WIRE)–Takeda präsentiert Ergebnisse aus der Phase-3-Studie ALTA-1L, die die intrakranielle Wirksamkeit von ALUNBRIG® (Brigatinib) gegenüber Crizotinib in der Erstlinientherapie...
Latest News

Takeda apresenta resultados do ensaio ALTA-1L de fase 3 que destaca a eficácia intracraniana do ALUNBRIG® (brigatinibe) em relação ao crizotinibe no câncer de pulmão de não pequenas células ALK+ avançado de primeira linha

Newsemia
CAMBRIDGE, Massachusetts e OSAKA, Japão–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) anunciou hoje que os dados de eficácia intracraniana do ensaio Fase 3 ALTA-1L (sigla...
Latest News

Takeda présentera les résultats de l'essai ALTA-1L de phase 3 soulignant l'efficacité intracrânienne d'ALUNBRIG® (brigatinib) en comparaison avec Crizotinib, dans le traitement de première intention du cancer du poumon à…

Newsemia
CAMBRIDGE, Massachusetts, & OSAKA, Japon–(BUSINESS WIRE)–Takeda présentera les résultats de l’essai ALTA-1L de phase 3 soulignant l’efficacité intracrânienne d’ALUNBRIG® (brigatinib) en comparaison avec Crizotinib, dans...
Latest News

Samenvatting: Takeda komt met resulaten van fase 3 ALTA-1L Trial Intracranial Efficacy van ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell longkanker

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–– Bij patiënten met hersenmetastasen op de basislijn heeft ALUNBRIG het risico van progressie in de hersenen of de dood...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World